Oral palonosetron noninferior to IV formulation for CINV prevention
the ONA take:
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting (CINV), according to a study published in the October 2015 issue of the journal Supportive Care in Cancer.
For the study, a team of researchers led by Prof. Dr. med. Meinolf Karthaus of the Department of Hematology and Oncology at Klinikum Neuperlach in Munich, Germany, sought to compare the efficacy and safety of oral palonosetron with intravenous palonosetron for the prevention cisplatin-based highly emetogenic chemotherapy.
Researchers enrolled 743 chemotherapy-naive adults with malignant solid tumors initiating cisplatin-based chemotherapy. Patients were randomly assigned to receive palonosetron 0.50mg orally or 0.25mg intravenously plus oral dexamethasone.
Results showed that the complete response rate in the acute phase was higher than 86% in both treatment arms and the safety profiles were comparable.
Treatment-emergent adverse events related to palonosetron occurred in 3.2% of patients in the oral palonosetron group and 6.5% in the intravenous group.
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|